Regulatory Spine Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8 byJosh SandbergDecember 11, 2025
Spine Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield byJosh SandbergApril 28, 2025
Neuro Spine Mainstay Medical Announces Positive Results from the Landmark ReActiv8® RESTORE Clinical Trial byTim AllenJanuary 16, 2025
Neuro Spine Top Stories Mainstay Medical Announces New ICD-10 Diagnostic Code for Multifidus Muscle Dysfunction byTim AllenOctober 3, 2024
Neuro Regulatory Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System™ byJosh SandbergJuly 9, 2024
Spine Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up byJosh SandbergMarch 19, 2024
Financial Mainstay Medical Announces US$125 Million Equity Financing Transaction byJosh SandbergFebruary 26, 2024
Neuro Regulatory Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System™ byJosh SandbergFebruary 12, 2024
Neuro Spine Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States byJosh SandbergAugust 29, 2023
Neuro Spine Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom byJosh SandbergJuly 20, 2023
